Topic: cardiovascular outcomes
Despite outcomes data that left analysts less-than-enthused, Eli Lilly's Trulicity scored the FDA's nod to lower CV risks in a first-ever approval.
An SGLT2 arms race is currently underway for heart failure patients, and not without reason: the market will likely continue to boom this decade.
Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.
Amarin’s newest campaign to highlight heart risks takes on not only supermarket fish oil, but also discredited niacin and fenofibrate drugs.
Epanova's failure to prove a it could cut heart risks could give Amarin's fellow fish oil-derived Vascepa a clearer shot at blockbuster sales.
The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.
On the heels of Novartis' $9.7 billion pick-up of MedCo, Amarin is now back at the center of the rumor mill among pharma M&A speculators.
One year after its landmark Reduce-It CV outcomes trial, Amarin has new data showing its Vascepa may help halt the progress of arterial plaque.
Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.
In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.